PROCESSA PHARMACEUTICALS INC (PCSA) Stock Price, Quote, News and Overview
NASDAQ:PCSA - Nasdaq - US74275C3043 - Common Stock - Currency: USD
PCSA Quote, Performance and Key Statistics
NASDAQ:PCSA (2/21/2025, 8:00:00 PM)
0.53
-0.02 (-3.65%)
The current stock price of PCSA is 0.53 USD. In the past month the price decreased by -27.4%. In the past year, price decreased by -75.91%.
PCSA Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
| JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
| MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
| PFE | PFIZER INC | 8.46 | 149.04B | ||
| SNY | SANOFI-ADR | 13.58 | 136.54B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
| GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
| ZTS | ZOETIS INC | 27.1 | 72.39B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Related stock screener links
About PCSA
Company Profile
Processa Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug products for the treatment of serious medical conditions. The company is headquartered in Hanover Maryland, Maryland and currently employs 13 full-time employees. The company went IPO on 2013-10-07. The firm is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDA’s) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine, resulting in a positive response in gemcitabine patients and some gemcitabine treatment-resistant patients. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38).
Company Info
PROCESSA PHARMACEUTICALS INC
7380 Coca Cola Dr Ste 106
Hanover Maryland MARYLAND 21076 US
CEO: David Young
Employees: 13
Company Website: https://www.processapharmaceuticals.com/
Phone: 14437763133
PROCESSA PHARMACEUTICALS INC / PCSA FAQ
What is the stock price of PROCESSA PHARMACEUTICALS INC today?
The current stock price of PCSA is 0.53 USD. The price decreased by -3.65% in the last trading session.
What is the ticker symbol for PROCESSA PHARMACEUTICALS INC stock?
The exchange symbol of PROCESSA PHARMACEUTICALS INC is PCSA and it is listed on the Nasdaq exchange.
On which exchange is PCSA stock listed?
PCSA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PROCESSA PHARMACEUTICALS INC stock?
7 analysts have analysed PCSA and the average price target is 6.12 USD. This implies a price increase of 1054.72% is expected in the next year compared to the current price of 0.53. Check the PROCESSA PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROCESSA PHARMACEUTICALS INC worth?
PROCESSA PHARMACEUTICALS INC (PCSA) has a market capitalization of 2.51M USD. This makes PCSA a Nano Cap stock.
How many employees does PROCESSA PHARMACEUTICALS INC have?
PROCESSA PHARMACEUTICALS INC (PCSA) currently has 13 employees.
What are the support and resistance levels for PROCESSA PHARMACEUTICALS INC (PCSA) stock?
PROCESSA PHARMACEUTICALS INC (PCSA) has a resistance level at 0.84. Check the full technical report for a detailed analysis of PCSA support and resistance levels.
Should I buy PROCESSA PHARMACEUTICALS INC (PCSA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of PCSA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of PCSA, evaluating the profitability, health, valuation and growth aspects
- PROCESSA PHARMACEUTICALS INC (PCSA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROCESSA PHARMACEUTICALS INC (PCSA) Sales and EPS estimates to see what analysts future expectations are.
- PROCESSA PHARMACEUTICALS INC (PCSA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROCESSA PHARMACEUTICALS INC (PCSA) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROCESSA PHARMACEUTICALS INC (PCSA) Stock Chart to make your own analysis
- PROCESSA PHARMACEUTICALS INC (PCSA) Latest news and press-releases to stay up to date.
Does PROCESSA PHARMACEUTICALS INC (PCSA) stock pay dividends?
PCSA does not pay a dividend.
When does PROCESSA PHARMACEUTICALS INC (PCSA) report earnings?
PROCESSA PHARMACEUTICALS INC (PCSA) will report earnings on 2025-03-27, after the market close.
What is the Price/Earnings (PE) ratio of PROCESSA PHARMACEUTICALS INC (PCSA)?
PROCESSA PHARMACEUTICALS INC (PCSA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.85).
What is the Short Interest ratio of PROCESSA PHARMACEUTICALS INC (PCSA) stock?
The outstanding short interest for PROCESSA PHARMACEUTICALS INC (PCSA) is 21.21% of its float. Check the ownership tab for more information on the PCSA short interest.
PCSA Technical Analysis
PCSA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to PCSA. PCSA has a bad profitability rating. Also its financial health evaluation is rather negative.
PCSA Financial Highlights
Over the last trailing twelve months PCSA reported a non-GAAP Earnings per Share(EPS) of -4.85. The EPS increased by 78.69% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -233.23% | ||
| ROE | -309.78% | ||
| Debt/Equity | 0 |
PCSA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to PCSA. The Buy consensus is the average rating of analysts ratings from 7 analysts.